



**Innovation combining BT, B13, and GPE in a skincare product improves skin condition by decreasing transdermal water loss and increasing skin hydration and elasticity in volunteers with aging skin.**

OncoBone

[oncobone.com](http://oncobone.com)

---

## PRODUCT/SERVICE BACKGROUND INFORMATION

We performed a study to demonstrate effects of a novel skincare product containing three factors BT, B13 and GPE (BTB13G) on volunteers with normal aging skin in a 4-week blinded, placebo-controlled trial. The study included seven volunteers with normal aging skin whose skin condition was evaluated at baseline and during the study using Vapometer, Moisturemeter and Elastimeter devices to measure transepidermal water loss (TEWL), skin hydration and skin elasticity, respectively. The volunteers used placebo and BTB13G containing creams, and their skin condition was monitored for 4 weeks.

## WHAT IS THE COMPANY INTRODUCING TO THE MARKET/INDUSTRY?

Skin aging slows down generation of new cells from underlying stem cells, ultimately leading to age-related signs visible in our skin, such as formation of fine lines and deeper wrinkles. Changes observed in skin appearance include sagging, dryness, rough texture, hyperpigmentation and dull or uneven skin tone. A novel patented skincare innovation involving BTB13G has demonstrated to increase viability of stem cells. As viability of the stem cells increases, they can renew more rapidly. The new skin cells are more viable and can contribute to improved skin condition and more youthful looking skin, which has been demonstrated in our study.

## HOW WILL THIS NEW PRODUCT/SERVICE IMPACT THE INDUSTRY (BENEFITS)?

BTB13G cream decreased TEWL and increased skin hydration and elasticity. TEWL decreased after the first week of use. Skin hydration increased by 50% after 2 weeks of use and remained at higher levels compared to placebo for the duration of the study. Skin elasticity began to improve after 3 weeks of use and an increasing trend was observed at 4 weeks. Based on these results BTB13G has triple effects on skin that are likely caused by increased viability of skin stem cells. Based on these results, a novel skincare product series NOVA has been developed and launched to the market in November 2025.